Profile data is unavailable for this security.
About the company
Actinium Pharmaceuticals, Inc. specializes in the development of targeted radiotherapies. The Company is advancing its lead product candidate Actimab-A, a CD33 targeting therapeutic, as potential backbone therapy in acute myeloid leukemia (AML) and other myeloid malignancies leveraging the mutation agnostic alpha-emitter radioisotope payload Actinium-225 (Ac-225). The Company is engaged with the National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) for development of Actimab-A in AML and other myeloid malignancies. ATNM-400 is the Company's novel non-PSMA targeting Ac-225 radiotherapy for prostate cancer. Iomab-ACT, its conditioning candidate, is being developed to improve patient access and outcomes for potentially curative cell and gene therapies. Its Iomab-B program is an induction and conditioning agent prior to bone marrow transplant in patients with r/r AML, which it is seeking a potential strategic partner for the United States.
- Revenue in USD (TTM)90.00k
- Net income in USD-34.60m
- Incorporated2013
- Employees37.00
- LocationActinium Pharmaceuticals Inc100 Park Ave., 23Rd FloorNEW YORK 10017United StatesUSA
- Phone+1 (646) 677-3870
- Fax+1 (845) 818-3588
- Websitehttps://www.actiniumpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Werewolf Therapeutics Inc | 0.00 | -72.84m | 31.73m | 39.00 | -- | 1.04 | -- | -- | -1.62 | -1.62 | 0.00 | 0.6264 | 0.00 | -- | -- | 0.00 | -66.32 | -33.10 | -76.84 | -36.81 | -- | -- | -- | -593.05 | -- | -54.29 | 0.4829 | -- | -90.55 | -- | -88.70 | -- | -0.919 | -- |
| Jasper Therapeutics Inc | 0.00 | -91.02m | 31.90m | 64.00 | -- | 2.76 | -- | -- | -5.90 | -5.90 | 0.00 | 0.4135 | 0.00 | -- | -- | 0.00 | -116.04 | -75.11 | -147.54 | -86.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -10.55 | -- | -- | -- |
| Atara Biotherapeutics Inc | 151.93m | 23.40m | 32.09m | 38.00 | 2.03 | -- | 1.21 | 0.2112 | 2.19 | 2.19 | 12.81 | -5.08 | 1.76 | 3.99 | 93.55 | 993,006.60 | 27.07 | -67.79 | -- | -93.07 | 81.63 | -- | 15.40 | -558.47 | 1.02 | 15.24 | 8.31 | -- | 1,404.02 | -- | 69.07 | -- | -46.73 | -- |
| Onkure Therapeutics Inc | 0.00 | -81.21m | 32.79m | 46.00 | -- | 0.4936 | -- | -- | -12.78 | -12.78 | 0.00 | 4.90 | 0.00 | -- | -- | 0.00 | -107.93 | -48.73 | -115.20 | -53.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 31.94 | -- | 49.34 | -- |
| Promis Neurosciences Inc | 0.00 | -29.28m | 32.82m | 6.00 | -- | 3.57 | -- | -- | -18.62 | -18.62 | 0.00 | 4.27 | 0.00 | -- | -- | -- | -127.41 | -85.65 | -188.18 | -145.08 | -- | -- | -- | -3,184,250.00 | -- | -- | 0.00 | -- | -- | -- | 121.03 | -- | -- | -- |
| Bioqual Inc | 46.54m | 453.25k | 33.55m | 108.00 | 74.02 | 0.938 | 12.22 | 0.7209 | 0.5068 | 0.5068 | 52.03 | 39.99 | 0.7111 | -- | 3.19 | -- | 0.6926 | 4.12 | 0.7745 | 4.83 | 12.85 | 16.15 | 0.974 | 4.03 | -- | -- | 0.00 | 32.81 | -16.60 | 1.06 | -316.79 | -- | -36.99 | -6.51 |
| Cell Source Inc | 0.00 | -6.57m | 34.03m | -- | -- | -- | -- | -- | -0.1613 | -0.1613 | 0.00 | -0.4379 | 0.00 | -- | -- | -- | -2,039.39 | -1,758.85 | -- | -- | -- | -- | -- | -- | -- | -3.74 | -- | -- | -- | -- | -3.55 | -- | -- | -- |
| Actinium Pharmaceuticals Inc | 90.00k | -34.60m | 34.63m | 37.00 | -- | 2.51 | -- | 384.75 | -1.11 | -1.11 | 0.0029 | 0.4419 | 0.0013 | -- | -- | 2,432.43 | -50.05 | -43.20 | -55.95 | -47.84 | -- | -- | -38,443.33 | -7,408.74 | -- | -- | 0.0009 | -- | -100.00 | -- | 21.66 | -- | -29.66 | -- |
| Tvardi Therapeutics Inc | 4.02m | -13.95m | 34.90m | 10.00 | -- | 1.25 | -- | 8.67 | -8.36 | -8.36 | 0.7709 | 2.97 | 0.0891 | -- | -- | 402,400.00 | -30.87 | -36.79 | -40.26 | -41.45 | 100.00 | -- | -346.55 | -155.60 | -- | -- | 0.00 | -- | -65.96 | -18.53 | 40.20 | -- | 125.35 | -- |
| NextCure Inc | 0.00 | -58.01m | 35.11m | 43.00 | -- | 1.48 | -- | -- | -24.19 | -24.19 | 0.00 | 8.84 | 0.00 | -- | -- | 0.00 | -89.28 | -27.70 | -105.20 | -28.91 | -- | -- | -- | -1,336.59 | -- | -- | 0.00 | -- | -- | -- | 11.27 | -- | -32.45 | -- |
| Outlook Therapeutics Inc | 1.51m | -62.42m | 36.02m | 17.00 | -- | -- | -- | 23.93 | -1.61 | -1.61 | 0.0432 | -0.5973 | 0.0635 | -- | -- | 88,548.23 | -263.36 | -240.08 | -- | -- | 70.78 | -- | -4,146.95 | -22,354.50 | 0.3067 | -200.54 | -- | -- | -- | -- | 17.17 | -- | -- | -- |
| Atossa Therapeutics Inc | 0.00 | -30.18m | 36.17m | 13.00 | -- | 0.7265 | -- | -- | -3.52 | -3.52 | 0.00 | 5.78 | 0.00 | -- | -- | 0.00 | -43.90 | -26.93 | -48.89 | -29.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 15.25 | -- | 20.02 | -- |
| Axe Compute Inc | 728.20k | -84.01m | 36.36m | 23.00 | -- | -- | -- | 49.94 | -120.02 | -120.66 | 1.29 | -100.94 | 0.1369 | 1.34 | 2.97 | 31,660.87 | -1,579.84 | -85.09 | -- | -113.42 | 50.24 | 61.31 | -11,536.93 | -1,267.27 | 0.0134 | -0.1392 | -- | -- | -0.2384 | 2.84 | 9.63 | -- | -18.60 | -- |
| PDS Biotechnology Corp | 0.00 | -34.88m | 36.70m | 24.00 | -- | 3.54 | -- | -- | -0.8194 | -0.8194 | 0.00 | 0.1982 | 0.00 | -- | -- | 0.00 | -80.05 | -57.93 | -125.74 | -68.38 | -- | -- | -- | -- | -- | -8.43 | 0.6552 | -- | -- | -- | 12.42 | -- | -- | -- |
| Veru Inc | 0.00 | -15.68m | 36.76m | 20.00 | -- | 1.83 | -- | -- | -1.07 | -1.55 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -34.75 | -47.51 | -44.42 | -59.79 | -- | -- | -- | -188.81 | -- | -- | 0.00 | -- | -- | -- | 55.53 | -- | -60.02 | -- |
Data as of Feb 13 2026. Currency figures normalised to Actinium Pharmaceuticals Inc's reporting currency: US Dollar USD
15.92%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 1.25m | 4.01% |
| District 2 Capital LPas of 08 Nov 2024 | 769.45k | 2.47% |
| Millennium Management LLCas of 30 Sep 2025 | 624.70k | 2.00% |
| Acadian Asset Management LLCas of 31 Dec 2025 | 606.34k | 1.94% |
| Renaissance Technologies LLCas of 31 Dec 2025 | 390.78k | 1.25% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 360.90k | 1.16% |
| Geode Capital Management LLCas of 31 Dec 2025 | 328.99k | 1.06% |
| Two Sigma Investments LPas of 30 Sep 2025 | 234.29k | 0.75% |
| Gagnon Securities LLCas of 31 Dec 2025 | 201.81k | 0.65% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 196.38k | 0.63% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
